Ischemic Serum Activates Stem Cells for Brain Injury Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current stem cell therapies face challenges such as long culture times, variability in stem cell characteristics, reduced viability, and ethical concerns with fetal bovine serum, particularly in treating brain injuries, where timely transplantation and maintaining stem cell viability are critical.
Innovation Solution
The use of ischemic serum as a stimulant to promote stem cell activation, increasing growth factor secretion, proliferation rate, and viability, and enhancing migration to injured sites, thereby reducing culture time and minimizing cell loss.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If stem cells are cultured using conventional methods (fetal bovine serum) to achieve sufficient concentration for therapy, then the cell concentration reaches therapeutic levels, but the culture time exceeds 4-5 weeks which delays treatment
Solution Approach 1:
The patent changes the chemical composition parameters of the culture medium by replacing fetal bovine serum with ischemic serum, which contains unique growth factors and cytokines that accelerate stem cell proliferation, thereby reducing culture time while achieving therapeutic concentrations
Solution Approach 2:
Ischemic serum acts as an intermediary substance that mediates stem cell activation and proliferation. The serum contains bioactive molecules that serve as signaling intermediaries to stimulate rapid cell division and prepare stem cells for transplantation
2Reliability
If stem cells are transplanted without adequate activation, then transplantation can proceed, but the therapeutic effect is insufficient and cells may not survive in toxic environments
Solution Approach 1:
The patent applies preliminary activation treatment to stem cells using ischemic serum before transplantation. This pre-treatment prepares the cells by enhancing their survival capabilities, promoting differentiation toward therapeutic phenotypes, and activating protective mechanisms against the toxic transplant environment
Solution Approach 2:
The patent converts the harmful ischemic environment (which produces toxic byproducts) into a beneficial activation stimulus. By exposing stem cells to ischemic serum containing these harmful molecules, the cells develop resistance and adaptive responses that improve their survival and therapeutic effectiveness when transplanted into ischemic tissues
3Stability of the object's composition
If fetal bovine serum is used for stem cell culture, then cells can be maintained, but ethical issues arise and zoonotic disease transmission risk exists
Solution Approach 1:
The patent replaces the problematic fetal bovine serum with human-derived ischemic serum, which is obtained from surgical waste material. This substitution eliminates ethical concerns about fetal tissue use and reduces zoonotic disease risks while maintaining effective stem cell culture conditions
Solution Approach 2:
The patent uses human ischemic serum to culture human stem cells, creating a self-compatible system. The serum and cells share the same species origin, eliminating the need for xenotransplantation and associated ethical and safety concerns
Data Source
AI summary
The present invention relates to a composition comprising an ischemic serum for promoting the activation of a stem cell, to a method for promoting the activation of a stem cell and to a stem cell, the activation of which is promoted by the composition or the method. The ischemic serum according to the present invention may stimulate the stem cell to facilitate the secretion of a growth factor, improve survival rate, improve mobility to an injured part, improve proliferation rate and maintain characteristics of the stem cell, thus promoting an activation of the stem cell such that the stem cell becomes suitable for transplantation of the stem cell to a patient having a brain injury.